Business
Adagio Medical Announces Publication of Pre-Clinical Results for Next Generation Ventricular Ablation Catheter
Highlights Improvements in Next Generation ULTA Catheter, Including Potential 50-75% Reduction in Ablation Time LAGUNA HILLS, Calif.--(BUSINESS WIRE)--
About this update from Adagio Medical Holdings, Inc
[{"type":"text","content":"\nHighlights Improvements in Next Generation ULTA Catheter, Including Potential 50-75% Reduction in Ablation Time\n\n\n LAGUNA HILLS, Calif.--(BUSINESS WIRE)--\nAdagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the publication of pre-clinical results of the Company’s next generation ultra-low temperature ablation (“ULTA”) technology designed to treat ventricular arrhythmias. The publication, which is titled “Initial Pre‐Clinical Evaluation of the Augmented Ultra‐Low Temperature Cryoablation Catheter for Ventricular Ablation” was published in the Journal of Cardiovascular Electrophysiology and describes significant functional improvements in ablation catheter performance compared to the Company’s first generation vCLAS™ ULTA catheter, including improved handling characteristics, better compatibility with standard laboratory practices and potential for 50-75% reduction in ablation time. The publication is authored by physicians from several leading ventricular ablation programs in Germany, Belgium and Canada\n\n\n“The investigators in this study all have extensive experience performing procedures with first-generation vCLASTM catheters, which has provided us each with deep appreciation of the unique advantages of ULTA in ventricular ablation, including titratable lesion depth exceeding 10 millimeters,” said Katia Dyrda MD FRCPC MSc Eng, Electrophysiologist Cardiologist, Montreal Heart Institute, Associate Clinical Professor, University of Montreal and a lead author of the study. “Remarkably, this next- generation ULTA system achieves these same advantages with more powerful and faster ablations using a smaller, 8.5 French-size catheter with handling characteristics equivalent to those of our standard RF catheters. These technical advances translate into a number of clinical advantages, including potential reduction in procedure time by as much as 30 minutes compared to first-generation of ULTA.”\n\n\nAdagio’s next generation proprietary ULTA technology achieves ablation temperatures of approximately -170°C enabling highly efficient, single-freeze applications that have been shown to produce 5-millimeter-deep lesions in as little as 15 seconds and 12.5-millimeter-deep lesions in approximately 120 s...